Literature DB >> 17289169

Cryptosporidium parvum spermidine/spermine N1-acetyltransferase exhibits different characteristics from the host enzyme.

Nigel Yarlett1, Gang Wu, W Ray Waters, James A Harp, Michael J Wannemuehler, Mary Morada, Demos Athanasopoulos, Martha P Martinez, Steve J Upton, Laurence J Marton, Benjamin J Frydman.   

Abstract

Cryptosporidosis is a severe opportunistic infection of immuno-compromised individuals for which no reliable therapy exists. The parasite scavenges host-derived polyamines, particularly spermine, which is then converted to the lower polyamines by the combined action of spermidine/spermine N(1)-acetyltransferase (SSAT) and polyamine oxidase (PAO). We have isolated and expressed the Cryptosporidium parvum SSAT for kinetic and molecular comparison with the host enzyme. The CpSSAT is a homotetramer with a subunit molecular mass of 18 kDa and low sequence similarity to higher eukaryotes but maintains the critical arginine residues in the active site. The CpSSAT had an activity of 299 nmol(-1)min(-1)(mg of protein)(-1) and exhibits an ordered Bi-Bi kinetics with preferred substrate specificity for spermine. Polyamine analogues having unsaturated central carbons were found to exhibit mixed inhibition kinetics of the CpSSAT. The cis-analogues were more effective inhibitors of the CpSSAT with lower K(i) values than the trans-analogues. Experiments aimed at determining the ratio of the time of the analogue in the enzyme active site to that spent out (in-out time: delta ln E/deltat) confirmed the higher efficiency of the cis-analogues as inhibitors of the CpSSAT. The results of this study reveal that the C. parvum SSAT may provide a rational target for drug design.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289169     DOI: 10.1016/j.molbiopara.2007.01.004

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  7 in total

1.  Crystal structure of the novel PaiA N-acetyltransferase from Thermoplasma acidophilum involved in the negative control of sporulation and degradative enzyme production.

Authors:  E V Filippova; L Shuvalova; G Minasov; O Kiryukhina; Y Zhang; S Clancy; I Radhakrishnan; A Joachimiak; W F Anderson
Journal:  Proteins       Date:  2011-06-01

2.  Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model.

Authors:  Nigel Yarlett; W Ray Waters; James A Harp; Michael J Wannemuehler; Mary Morada; Josephine Bellcastro; Steve J Upton; Laurence J Marton; Benjamin J Frydman
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

3.  Kinetics of human pyrroline-5-carboxylate reductase in L-thioproline metabolism.

Authors:  Sagar M Patel; Javier Seravalli; Kyle M Stiers; John J Tanner; Donald F Becker
Journal:  Amino Acids       Date:  2021-11-18       Impact factor: 3.520

4.  Cryptosporidium parvum induces an endoplasmic stress response in the intestinal adenocarcinoma HCT-8 cell line.

Authors:  Mary Morada; Lakhsmi Pendyala; Gang Wu; Salim Merali; Nigel Yarlett
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

5.  Radioprotective efficacy and toxicity of a new family of aminothiol analogs.

Authors:  Richard R Copp; Daniel D Peebles; Cheryl M Soref; William E Fahl
Journal:  Int J Radiat Biol       Date:  2013-02-20       Impact factor: 2.694

6.  Disease variants of human Δ1-pyrroline-5-carboxylate reductase 2 (PYCR2).

Authors:  Sagar M Patel; Javier Seravalli; Xinwen Liang; John J Tanner; Donald F Becker
Journal:  Arch Biochem Biophys       Date:  2021-03-24       Impact factor: 4.114

7.  The Apicomplexa-specific glucosamine-6-phosphate N-acetyltransferase gene family encodes a key enzyme for glycoconjugate synthesis with potential as therapeutic target.

Authors:  Marta Cova; Borja López-Gutiérrez; Sara Artigas-Jerónimo; Aida González-Díaz; Giulia Bandini; Steven Maere; Lorenzo Carretero-Paulet; Luis Izquierdo
Journal:  Sci Rep       Date:  2018-03-05       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.